nodes	percent_of_prediction	percent_of_DWPC	metapath
Oritavancin—Connective tissue disorder—Gemcitabine—lung cancer	0.00208	0.00208	CcSEcCtD
Oritavancin—Cellulitis—Doxorubicin—lung cancer	0.00205	0.00205	CcSEcCtD
Oritavancin—Diarrhoea—Teniposide—lung cancer	0.00202	0.00202	CcSEcCtD
Oritavancin—Cardiac disorder—Irinotecan—lung cancer	0.00202	0.00202	CcSEcCtD
Oritavancin—Infestation NOS—Etoposide—lung cancer	0.00201	0.00201	CcSEcCtD
Oritavancin—Infestation—Etoposide—lung cancer	0.00201	0.00201	CcSEcCtD
Oritavancin—Hyperuricaemia—Doxorubicin—lung cancer	0.00201	0.00201	CcSEcCtD
Oritavancin—Erythema multiforme—Gemcitabine—lung cancer	0.002	0.002	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Topotecan—lung cancer	0.00199	0.00199	CcSEcCtD
Oritavancin—Infestation NOS—Paclitaxel—lung cancer	0.00197	0.00197	CcSEcCtD
Oritavancin—Infestation—Paclitaxel—lung cancer	0.00197	0.00197	CcSEcCtD
Oritavancin—Blood bilirubin increased—Doxorubicin—lung cancer	0.00197	0.00197	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Erlotinib—lung cancer	0.00197	0.00197	CcSEcCtD
Oritavancin—Cardiac disorder—Gemcitabine—lung cancer	0.00197	0.00197	CcSEcCtD
Oritavancin—Immune system disorder—Irinotecan—lung cancer	0.00196	0.00196	CcSEcCtD
Oritavancin—Mediastinal disorder—Irinotecan—lung cancer	0.00196	0.00196	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Docetaxel—lung cancer	0.00196	0.00196	CcSEcCtD
Oritavancin—Myalgia—Vinorelbine—lung cancer	0.00195	0.00195	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—lung cancer	0.00194	0.00194	CcSEcCtD
Oritavancin—Connective tissue disorder—Cisplatin—lung cancer	0.00194	0.00194	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Docetaxel—lung cancer	0.00192	0.00192	CcSEcCtD
Oritavancin—Immune system disorder—Gemcitabine—lung cancer	0.00191	0.00191	CcSEcCtD
Oritavancin—Mediastinal disorder—Gemcitabine—lung cancer	0.00191	0.00191	CcSEcCtD
Oritavancin—Blood uric acid increased—Doxorubicin—lung cancer	0.0019	0.0019	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Topotecan—lung cancer	0.00189	0.00189	CcSEcCtD
Oritavancin—Vomiting—Teniposide—lung cancer	0.00188	0.00188	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Erlotinib—lung cancer	0.00187	0.00187	CcSEcCtD
Oritavancin—Rash—Teniposide—lung cancer	0.00186	0.00186	CcSEcCtD
Oritavancin—Dermatitis—Teniposide—lung cancer	0.00186	0.00186	CcSEcCtD
Oritavancin—Infection—Vinorelbine—lung cancer	0.00186	0.00186	CcSEcCtD
Oritavancin—Headache—Teniposide—lung cancer	0.00185	0.00185	CcSEcCtD
Oritavancin—Bronchospasm—Docetaxel—lung cancer	0.00185	0.00185	CcSEcCtD
Oritavancin—Nervous system disorder—Vinorelbine—lung cancer	0.00184	0.00184	CcSEcCtD
Oritavancin—Cardiac disorder—Cisplatin—lung cancer	0.00183	0.00183	CcSEcCtD
Oritavancin—Tachycardia—Vinorelbine—lung cancer	0.00183	0.00183	CcSEcCtD
Oritavancin—Skin disorder—Vinorelbine—lung cancer	0.00182	0.00182	CcSEcCtD
Oritavancin—Immune system disorder—Cisplatin—lung cancer	0.00178	0.00178	CcSEcCtD
Oritavancin—Mediastinal disorder—Cisplatin—lung cancer	0.00178	0.00178	CcSEcCtD
Oritavancin—Nausea—Teniposide—lung cancer	0.00175	0.00175	CcSEcCtD
Oritavancin—Anaemia—Irinotecan—lung cancer	0.00175	0.00175	CcSEcCtD
Oritavancin—Oedema peripheral—Paclitaxel—lung cancer	0.00175	0.00175	CcSEcCtD
Oritavancin—Connective tissue disorder—Paclitaxel—lung cancer	0.00174	0.00174	CcSEcCtD
Oritavancin—Urticaria—Topotecan—lung cancer	0.00174	0.00174	CcSEcCtD
Oritavancin—Malnutrition—Cisplatin—lung cancer	0.00172	0.00172	CcSEcCtD
Oritavancin—Erythema multiforme—Etoposide—lung cancer	0.00171	0.00171	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Vinorelbine—lung cancer	0.00171	0.00171	CcSEcCtD
Oritavancin—Anaemia—Gemcitabine—lung cancer	0.0017	0.0017	CcSEcCtD
Oritavancin—Cardiac disorder—Etoposide—lung cancer	0.00168	0.00168	CcSEcCtD
Oritavancin—Erythema multiforme—Paclitaxel—lung cancer	0.00168	0.00168	CcSEcCtD
Oritavancin—Infestation NOS—Docetaxel—lung cancer	0.00167	0.00167	CcSEcCtD
Oritavancin—Infestation—Docetaxel—lung cancer	0.00167	0.00167	CcSEcCtD
Oritavancin—Hypersensitivity—Vinblastine—lung cancer	0.00166	0.00166	CcSEcCtD
Oritavancin—Cardiac disorder—Paclitaxel—lung cancer	0.00165	0.00165	CcSEcCtD
Oritavancin—Immune system disorder—Etoposide—lung cancer	0.00163	0.00163	CcSEcCtD
Oritavancin—Mediastinal disorder—Etoposide—lung cancer	0.00163	0.00163	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Vinorelbine—lung cancer	0.00162	0.00162	CcSEcCtD
Oritavancin—Hypersensitivity—Topotecan—lung cancer	0.00161	0.00161	CcSEcCtD
Oritavancin—Immune system disorder—Paclitaxel—lung cancer	0.0016	0.0016	CcSEcCtD
Oritavancin—Mediastinal disorder—Paclitaxel—lung cancer	0.0016	0.0016	CcSEcCtD
Oritavancin—Anaemia—Cisplatin—lung cancer	0.00159	0.00159	CcSEcCtD
Oritavancin—Myalgia—Gemcitabine—lung cancer	0.00157	0.00157	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	0.00156	0.00156	CcSEcCtD
Oritavancin—Pruritus—Topotecan—lung cancer	0.00155	0.00155	CcSEcCtD
Oritavancin—Malnutrition—Paclitaxel—lung cancer	0.00154	0.00154	CcSEcCtD
Oritavancin—Diarrhoea—Vinblastine—lung cancer	0.00154	0.00154	CcSEcCtD
Oritavancin—Infection—Irinotecan—lung cancer	0.00153	0.00153	CcSEcCtD
Oritavancin—Pruritus—Erlotinib—lung cancer	0.00153	0.00153	CcSEcCtD
Oritavancin—Nervous system disorder—Irinotecan—lung cancer	0.00151	0.00151	CcSEcCtD
Oritavancin—Diarrhoea—Topotecan—lung cancer	0.0015	0.0015	CcSEcCtD
Oritavancin—Infection—Gemcitabine—lung cancer	0.00149	0.00149	CcSEcCtD
Oritavancin—Dizziness—Vinblastine—lung cancer	0.00149	0.00149	CcSEcCtD
Oritavancin—Urticaria—Vinorelbine—lung cancer	0.00149	0.00149	CcSEcCtD
Oritavancin—Diarrhoea—Erlotinib—lung cancer	0.00148	0.00148	CcSEcCtD
Oritavancin—Oedema peripheral—Docetaxel—lung cancer	0.00148	0.00148	CcSEcCtD
Oritavancin—Connective tissue disorder—Docetaxel—lung cancer	0.00148	0.00148	CcSEcCtD
Oritavancin—Nervous system disorder—Gemcitabine—lung cancer	0.00148	0.00148	CcSEcCtD
Oritavancin—Myalgia—Cisplatin—lung cancer	0.00146	0.00146	CcSEcCtD
Oritavancin—Skin disorder—Gemcitabine—lung cancer	0.00146	0.00146	CcSEcCtD
Oritavancin—Anaemia—Etoposide—lung cancer	0.00145	0.00145	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.00145	0.00145	CcSEcCtD
Oritavancin—Dizziness—Topotecan—lung cancer	0.00145	0.00145	CcSEcCtD
Oritavancin—Vomiting—Vinblastine—lung cancer	0.00143	0.00143	CcSEcCtD
Oritavancin—Dizziness—Erlotinib—lung cancer	0.00143	0.00143	CcSEcCtD
Oritavancin—Anaemia—Paclitaxel—lung cancer	0.00143	0.00143	CcSEcCtD
Oritavancin—Erythema multiforme—Docetaxel—lung cancer	0.00142	0.00142	CcSEcCtD
Oritavancin—Headache—Vinblastine—lung cancer	0.00141	0.00141	CcSEcCtD
Oritavancin—Angioedema—Paclitaxel—lung cancer	0.00141	0.00141	CcSEcCtD
Oritavancin—Cardiac disorder—Docetaxel—lung cancer	0.00139	0.00139	CcSEcCtD
Oritavancin—Infection—Cisplatin—lung cancer	0.00139	0.00139	CcSEcCtD
Oritavancin—Vomiting—Topotecan—lung cancer	0.00139	0.00139	CcSEcCtD
Oritavancin—Hypoglycaemia—Doxorubicin—lung cancer	0.00139	0.00139	CcSEcCtD
Oritavancin—Rash—Topotecan—lung cancer	0.00138	0.00138	CcSEcCtD
Oritavancin—Hypersensitivity—Vinorelbine—lung cancer	0.00138	0.00138	CcSEcCtD
Oritavancin—Dermatitis—Topotecan—lung cancer	0.00138	0.00138	CcSEcCtD
Oritavancin—Vomiting—Erlotinib—lung cancer	0.00138	0.00138	CcSEcCtD
Oritavancin—Nervous system disorder—Cisplatin—lung cancer	0.00138	0.00138	CcSEcCtD
Oritavancin—Headache—Topotecan—lung cancer	0.00137	0.00137	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.00137	0.00137	CcSEcCtD
Oritavancin—Tachycardia—Cisplatin—lung cancer	0.00137	0.00137	CcSEcCtD
Oritavancin—Rash—Erlotinib—lung cancer	0.00137	0.00137	CcSEcCtD
Oritavancin—Dermatitis—Erlotinib—lung cancer	0.00136	0.00136	CcSEcCtD
Oritavancin—Skin disorder—Cisplatin—lung cancer	0.00136	0.00136	CcSEcCtD
Oritavancin—Immune system disorder—Docetaxel—lung cancer	0.00136	0.00136	CcSEcCtD
Oritavancin—Headache—Erlotinib—lung cancer	0.00136	0.00136	CcSEcCtD
Oritavancin—Mediastinal disorder—Docetaxel—lung cancer	0.00135	0.00135	CcSEcCtD
Oritavancin—Eosinophilia—Methotrexate—lung cancer	0.00134	0.00134	CcSEcCtD
Oritavancin—Nausea—Vinblastine—lung cancer	0.00134	0.00134	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Irinotecan—lung cancer	0.00133	0.00133	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.00133	0.00133	CcSEcCtD
Oritavancin—Pruritus—Vinorelbine—lung cancer	0.00132	0.00132	CcSEcCtD
Oritavancin—Myalgia—Paclitaxel—lung cancer	0.00131	0.00131	CcSEcCtD
Oritavancin—Malnutrition—Docetaxel—lung cancer	0.00131	0.00131	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.0013	0.0013	CcSEcCtD
Oritavancin—Nausea—Topotecan—lung cancer	0.0013	0.0013	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Gemcitabine—lung cancer	0.0013	0.0013	CcSEcCtD
Oritavancin—Nausea—Erlotinib—lung cancer	0.00129	0.00129	CcSEcCtD
Oritavancin—Diarrhoea—Vinorelbine—lung cancer	0.00128	0.00128	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Cisplatin—lung cancer	0.00128	0.00128	CcSEcCtD
Oritavancin—Infection—Etoposide—lung cancer	0.00128	0.00128	CcSEcCtD
Oritavancin—Tachycardia—Etoposide—lung cancer	0.00125	0.00125	CcSEcCtD
Oritavancin—Infection—Paclitaxel—lung cancer	0.00125	0.00125	CcSEcCtD
Oritavancin—Skin disorder—Etoposide—lung cancer	0.00125	0.00125	CcSEcCtD
Oritavancin—Dizziness—Vinorelbine—lung cancer	0.00124	0.00124	CcSEcCtD
Oritavancin—Nervous system disorder—Paclitaxel—lung cancer	0.00124	0.00124	CcSEcCtD
Oritavancin—Tachycardia—Paclitaxel—lung cancer	0.00123	0.00123	CcSEcCtD
Oritavancin—Skin disorder—Paclitaxel—lung cancer	0.00122	0.00122	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Doxorubicin—lung cancer	0.00122	0.00122	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Cisplatin—lung cancer	0.00121	0.00121	CcSEcCtD
Oritavancin—Anaemia—Docetaxel—lung cancer	0.00121	0.00121	CcSEcCtD
Oritavancin—Infestation NOS—Methotrexate—lung cancer	0.00121	0.00121	CcSEcCtD
Oritavancin—Infestation—Methotrexate—lung cancer	0.00121	0.00121	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Doxorubicin—lung cancer	0.0012	0.0012	CcSEcCtD
Oritavancin—Vomiting—Vinorelbine—lung cancer	0.00119	0.00119	CcSEcCtD
Oritavancin—Rash—Vinorelbine—lung cancer	0.00118	0.00118	CcSEcCtD
Oritavancin—Dermatitis—Vinorelbine—lung cancer	0.00118	0.00118	CcSEcCtD
Oritavancin—Headache—Vinorelbine—lung cancer	0.00117	0.00117	CcSEcCtD
Oritavancin—Eosinophilia—Doxorubicin—lung cancer	0.00116	0.00116	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.00115	0.00115	CcSEcCtD
Oritavancin—Hypersensitivity—Irinotecan—lung cancer	0.00114	0.00114	CcSEcCtD
Oritavancin—Myalgia—Docetaxel—lung cancer	0.00111	0.00111	CcSEcCtD
Oritavancin—Nausea—Vinorelbine—lung cancer	0.00111	0.00111	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Etoposide—lung cancer	0.00111	0.00111	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.00111	0.00111	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Paclitaxel—lung cancer	0.00109	0.00109	CcSEcCtD
Oritavancin—Pruritus—Gemcitabine—lung cancer	0.00106	0.00106	CcSEcCtD
Oritavancin—Infection—Docetaxel—lung cancer	0.00106	0.00106	CcSEcCtD
Oritavancin—Diarrhoea—Irinotecan—lung cancer	0.00106	0.00106	CcSEcCtD
Oritavancin—Nervous system disorder—Docetaxel—lung cancer	0.00105	0.00105	CcSEcCtD
Oritavancin—Infestation NOS—Doxorubicin—lung cancer	0.00104	0.00104	CcSEcCtD
Oritavancin—Infestation—Doxorubicin—lung cancer	0.00104	0.00104	CcSEcCtD
Oritavancin—Tachycardia—Docetaxel—lung cancer	0.00104	0.00104	CcSEcCtD
Oritavancin—Skin disorder—Docetaxel—lung cancer	0.00104	0.00104	CcSEcCtD
Oritavancin—Hypersensitivity—Cisplatin—lung cancer	0.00103	0.00103	CcSEcCtD
Oritavancin—Diarrhoea—Gemcitabine—lung cancer	0.00103	0.00103	CcSEcCtD
Oritavancin—Erythema multiforme—Methotrexate—lung cancer	0.00102	0.00102	CcSEcCtD
Oritavancin—Dizziness—Irinotecan—lung cancer	0.00102	0.00102	CcSEcCtD
Oritavancin—Urticaria—Etoposide—lung cancer	0.00102	0.00102	CcSEcCtD
Oritavancin—Cardiac disorder—Methotrexate—lung cancer	0.00101	0.00101	CcSEcCtD
Oritavancin—Urticaria—Paclitaxel—lung cancer	0.001	0.001	CcSEcCtD
Oritavancin—Vomiting—Irinotecan—lung cancer	0.000982	0.000982	CcSEcCtD
Oritavancin—Immune system disorder—Methotrexate—lung cancer	0.000978	0.000978	CcSEcCtD
Oritavancin—Mediastinal disorder—Methotrexate—lung cancer	0.000976	0.000976	CcSEcCtD
Oritavancin—Rash—Irinotecan—lung cancer	0.000974	0.000974	CcSEcCtD
Oritavancin—Dermatitis—Irinotecan—lung cancer	0.000973	0.000973	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000973	0.000973	CcSEcCtD
Oritavancin—Headache—Irinotecan—lung cancer	0.000967	0.000967	CcSEcCtD
Oritavancin—Diarrhoea—Cisplatin—lung cancer	0.000959	0.000959	CcSEcCtD
Oritavancin—Vomiting—Gemcitabine—lung cancer	0.000956	0.000956	CcSEcCtD
Oritavancin—Rash—Gemcitabine—lung cancer	0.000949	0.000949	CcSEcCtD
Oritavancin—Dermatitis—Gemcitabine—lung cancer	0.000948	0.000948	CcSEcCtD
Oritavancin—Hypersensitivity—Etoposide—lung cancer	0.000946	0.000946	CcSEcCtD
Oritavancin—Malnutrition—Methotrexate—lung cancer	0.000943	0.000943	CcSEcCtD
Oritavancin—Headache—Gemcitabine—lung cancer	0.000942	0.000942	CcSEcCtD
Oritavancin—Hypersensitivity—Paclitaxel—lung cancer	0.000928	0.000928	CcSEcCtD
Oritavancin—Oedema peripheral—Doxorubicin—lung cancer	0.000924	0.000924	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Docetaxel—lung cancer	0.000922	0.000922	CcSEcCtD
Oritavancin—Connective tissue disorder—Doxorubicin—lung cancer	0.000922	0.000922	CcSEcCtD
Oritavancin—Nausea—Irinotecan—lung cancer	0.000917	0.000917	CcSEcCtD
Oritavancin—Pruritus—Etoposide—lung cancer	0.000909	0.000909	CcSEcCtD
Oritavancin—Nausea—Gemcitabine—lung cancer	0.000894	0.000894	CcSEcCtD
Oritavancin—Vomiting—Cisplatin—lung cancer	0.000892	0.000892	CcSEcCtD
Oritavancin—Pruritus—Paclitaxel—lung cancer	0.000891	0.000891	CcSEcCtD
Oritavancin—Erythema multiforme—Doxorubicin—lung cancer	0.000887	0.000887	CcSEcCtD
Oritavancin—Rash—Cisplatin—lung cancer	0.000884	0.000884	CcSEcCtD
Oritavancin—Dermatitis—Cisplatin—lung cancer	0.000883	0.000883	CcSEcCtD
Oritavancin—Diarrhoea—Etoposide—lung cancer	0.000879	0.000879	CcSEcCtD
Oritavancin—Anaemia—Methotrexate—lung cancer	0.000871	0.000871	CcSEcCtD
Oritavancin—Cardiac disorder—Doxorubicin—lung cancer	0.00087	0.00087	CcSEcCtD
Oritavancin—Diarrhoea—Paclitaxel—lung cancer	0.000862	0.000862	CcSEcCtD
Oritavancin—Dizziness—Etoposide—lung cancer	0.000849	0.000849	CcSEcCtD
Oritavancin—Immune system disorder—Doxorubicin—lung cancer	0.000847	0.000847	CcSEcCtD
Oritavancin—Mediastinal disorder—Doxorubicin—lung cancer	0.000845	0.000845	CcSEcCtD
Oritavancin—Dizziness—Paclitaxel—lung cancer	0.000833	0.000833	CcSEcCtD
Oritavancin—Nausea—Cisplatin—lung cancer	0.000833	0.000833	CcSEcCtD
Oritavancin—Vomiting—Etoposide—lung cancer	0.000817	0.000817	CcSEcCtD
Oritavancin—Malnutrition—Doxorubicin—lung cancer	0.000816	0.000816	CcSEcCtD
Oritavancin—Rash—Etoposide—lung cancer	0.00081	0.00081	CcSEcCtD
Oritavancin—Dermatitis—Etoposide—lung cancer	0.000809	0.000809	CcSEcCtD
Oritavancin—Headache—Etoposide—lung cancer	0.000805	0.000805	CcSEcCtD
Oritavancin—Myalgia—Methotrexate—lung cancer	0.000803	0.000803	CcSEcCtD
Oritavancin—Vomiting—Paclitaxel—lung cancer	0.000801	0.000801	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000797	0.000797	CcSEcCtD
Oritavancin—Rash—Paclitaxel—lung cancer	0.000794	0.000794	CcSEcCtD
Oritavancin—Dermatitis—Paclitaxel—lung cancer	0.000793	0.000793	CcSEcCtD
Oritavancin—Headache—Paclitaxel—lung cancer	0.000789	0.000789	CcSEcCtD
Oritavancin—Hypersensitivity—Docetaxel—lung cancer	0.000787	0.000787	CcSEcCtD
Oritavancin—Infection—Methotrexate—lung cancer	0.000764	0.000764	CcSEcCtD
Oritavancin—Nausea—Etoposide—lung cancer	0.000763	0.000763	CcSEcCtD
Oritavancin—Pruritus—Docetaxel—lung cancer	0.000755	0.000755	CcSEcCtD
Oritavancin—Nervous system disorder—Methotrexate—lung cancer	0.000755	0.000755	CcSEcCtD
Oritavancin—Anaemia—Doxorubicin—lung cancer	0.000755	0.000755	CcSEcCtD
Oritavancin—Nausea—Paclitaxel—lung cancer	0.000748	0.000748	CcSEcCtD
Oritavancin—Skin disorder—Methotrexate—lung cancer	0.000747	0.000747	CcSEcCtD
Oritavancin—Diarrhoea—Docetaxel—lung cancer	0.00073	0.00073	CcSEcCtD
Oritavancin—Dizziness—Docetaxel—lung cancer	0.000706	0.000706	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000701	0.000701	CcSEcCtD
Oritavancin—Myalgia—Doxorubicin—lung cancer	0.000695	0.000695	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.00069	0.00069	CcSEcCtD
Oritavancin—Vomiting—Docetaxel—lung cancer	0.000679	0.000679	CcSEcCtD
Oritavancin—Rash—Docetaxel—lung cancer	0.000673	0.000673	CcSEcCtD
Oritavancin—Dermatitis—Docetaxel—lung cancer	0.000673	0.000673	CcSEcCtD
Oritavancin—Headache—Docetaxel—lung cancer	0.000669	0.000669	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Methotrexate—lung cancer	0.000664	0.000664	CcSEcCtD
Oritavancin—Infection—Doxorubicin—lung cancer	0.000662	0.000662	CcSEcCtD
Oritavancin—Nervous system disorder—Doxorubicin—lung cancer	0.000653	0.000653	CcSEcCtD
Oritavancin—Tachycardia—Doxorubicin—lung cancer	0.00065	0.00065	CcSEcCtD
Oritavancin—Skin disorder—Doxorubicin—lung cancer	0.000647	0.000647	CcSEcCtD
Oritavancin—Nausea—Docetaxel—lung cancer	0.000634	0.000634	CcSEcCtD
Oritavancin—Urticaria—Methotrexate—lung cancer	0.000611	0.000611	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000607	0.000607	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000575	0.000575	CcSEcCtD
Oritavancin—Hypersensitivity—Methotrexate—lung cancer	0.000567	0.000567	CcSEcCtD
Oritavancin—Pruritus—Methotrexate—lung cancer	0.000544	0.000544	CcSEcCtD
Oritavancin—Urticaria—Doxorubicin—lung cancer	0.000529	0.000529	CcSEcCtD
Oritavancin—Diarrhoea—Methotrexate—lung cancer	0.000526	0.000526	CcSEcCtD
Oritavancin—Dizziness—Methotrexate—lung cancer	0.000509	0.000509	CcSEcCtD
Oritavancin—Hypersensitivity—Doxorubicin—lung cancer	0.000491	0.000491	CcSEcCtD
Oritavancin—Vomiting—Methotrexate—lung cancer	0.000489	0.000489	CcSEcCtD
Oritavancin—Rash—Methotrexate—lung cancer	0.000485	0.000485	CcSEcCtD
Oritavancin—Dermatitis—Methotrexate—lung cancer	0.000485	0.000485	CcSEcCtD
Oritavancin—Headache—Methotrexate—lung cancer	0.000482	0.000482	CcSEcCtD
Oritavancin—Pruritus—Doxorubicin—lung cancer	0.000471	0.000471	CcSEcCtD
Oritavancin—Nausea—Methotrexate—lung cancer	0.000457	0.000457	CcSEcCtD
Oritavancin—Diarrhoea—Doxorubicin—lung cancer	0.000456	0.000456	CcSEcCtD
Oritavancin—Dizziness—Doxorubicin—lung cancer	0.000441	0.000441	CcSEcCtD
Oritavancin—Vomiting—Doxorubicin—lung cancer	0.000424	0.000424	CcSEcCtD
Oritavancin—Rash—Doxorubicin—lung cancer	0.00042	0.00042	CcSEcCtD
Oritavancin—Dermatitis—Doxorubicin—lung cancer	0.00042	0.00042	CcSEcCtD
Oritavancin—Headache—Doxorubicin—lung cancer	0.000417	0.000417	CcSEcCtD
Oritavancin—Nausea—Doxorubicin—lung cancer	0.000396	0.000396	CcSEcCtD
